Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015
| Autor: | Ala-Eddine Deghmane, Eva Hong, Daniel Lévy-Bruhl, Denise Antona, I. Parent du Chatelet, L. Fonteneau, Muhamed-Kheir Taha |
|---|---|
| Přispěvatelé: | Santé publique France - French National Public Health Agency [Saint-Maurice, France], Centre National de Référence des Méningocoques et Haemophilus influenzae - National Reference Center Meningococci and Haemophilus influenzae (CNR), Institut Pasteur [Paris], No external funding was used for this work, however the work of the National Reference Center for meningococci was funded by Santé publique France and the Institut Pasteur., Institut Pasteur [Paris] (IP) |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Male Pediatrics Epidemiology MESH: Meningococcal Vaccines/administration & dosage MESH: Epidemics/statistics & numerical data Neisseria meningitidis Neisseria meningitidis Serogroup B Group B MESH: Genotype MESH: Meningococcal Infections/epidemiology 0302 clinical medicine MESH: Epidemics/prevention & control Cost of Illness [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases MESH: Neisseria meningitidis Serogroup B/pathogenicity MESH: Child Case fatality rate Medicine MESH: Vaccination/statistics & numerical data 030212 general & internal medicine MESH: Incidence Young adult Child MESH: Aged MESH: Middle Aged MESH: France/epidemiology Incidence (epidemiology) Incidence Vaccination MESH: Cost of Illness Middle Aged MESH: Infant MESH: Neisseria meningitidis Serogroup B/genetics 3. Good health MESH: Neisseria meningitidis/pathogenicity Infectious Diseases MESH: Neisseria meningitidis/genetics MESH: Young Adult Child Preschool Female France Microbiology (medical) Adult medicine.medical_specialty Adolescent Genotype 030106 microbiology Meningococcal C conjugate vaccination MESH: Meningococcal Infections/microbiology Meningococcal Vaccines Meningococcal disease 03 medical and health sciences Young Adult [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN] Humans Epidemics Disease burden MESH: Neisseria meningitidis Serogroup B/isolation & purification Aged MESH: Adolescent MESH: Humans business.industry MESH: Child Preschool Invasive meningococcal disease Infant MESH: Adult medicine.disease MESH: Male Meningococcal Infections MESH: Meningococcal Infections/mortality MESH: Neisseria meningitidis/isolation & purification [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie business MESH: Female |
| Zdroj: | Journal of Infection Journal of Infection, WB Saunders, 2017, 74 (6), pp.564-574. ⟨10.1016/j.jinf.2017.02.011⟩ Journal of Infection, 2017, 74 (6), pp.564-574. ⟨10.1016/j.jinf.2017.02.011⟩ |
| ISSN: | 1532-2742 0163-4453 |
| DOI: | 10.1016/j.jinf.2017.02.011⟩ |
| Popis: | International audience; OBJECTIVES:This work aimed to describe the epidemiology of invasive meningococcal disease (IMD) in France, 2006-2015, including group- and genotype-specific disease burden, incidence trends before and after introduction of meningococcal C conjugate vaccines (MCCV) in 2010, and factors influencing the case fatality rate.METHODS:Mandatory notification data on incidence and IMD case characteristics were used. Genotyping of invasive strains and whole genome sequencing were performed by the French National Reference Center. Vaccination coverage was estimated from the National Health Insurance Information System's reimbursement data.RESULTS:The decrease in annual IMD incidence rates (per 100,000 inhabitants) from 1.23 in 2006 to 0.78 in 2016 was mainly related to the decrease in group B IMD. Group C incidence decreased from 0.29 in 2006 to 0.13 in 2010 but increased thereafter in age groups not targeted by MCCV. From 2010 onwards, MCCV coverage gradually increased but remained below 25% in 15-19 year-olds in 2015. Age, clinical presentation and, to a lesser extent, clonal complex 11 were the most significant factors determining mortality.CONCLUSIONS:The limited impact of vaccination on group C IMD incidence may be explained by the emergence of a new epidemic cycle in 2011 and the low vaccination coverage rates among adolescents and young adults. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect